Please login
NASCOLA News - Bulletin Item
  

Posted: Thursday, September 12, 2013

Stago’s Ecarin Chromogenic Assay Provides Precise Research-Use DTI Results

 

We would like to announce that the ecarin chromogenic assay (ECA) from Diagnostica Stago, Inc. is a highly-specific tool for determining the exact direct thrombin inhibitor (DTI) concentration in plasma without any sample interferences.

 

Unlike the activated partial thromboplastin time (aPTT), Stago’s ECA results are independent of coagulation factors and plasmatic inhibitors within the sample; and as it is not influenced by lupus anticoagulants, the assay allows for specific determination of the drug levels. ECA is insensitive to heparin, LMWH, fondaparinux and direct factor Xa antagonists. Additionally, the ECA dose response results are linear and do not plateau at elevated concentrations.

 

The ECA kit may be adapted to Stago’s automated instruments, and the wide measuring range includes two reagent formats dedicated to each DTI type (ECA-H for recombinant hirudins, ECA-T for synthetic DTIs). Recombinant hirudins include desirudin (REVASC®, Iprivask®). Synthetic DTIs include argatroban (Argatroban), bivalirudin (Angiomax®), and dabigatran etexilate (Pradaxa®). Specific standards and controls are also available. The ECA kit is for research use only in the United States and Canada, and is not for use in diagnostic procedures.

 

REVASC is a registered trademark of Canyon Pharmaceuticals Group. Iprivask is a registered trademark of Novartis AG. Argatroban is manufactured, distributed and marketed by GlaxoSmithKline. Angiomax is a registered trademark of The Medicines Company. Pradaxa is a registered trademark of Boehringer Ingelheim Pharma GmbH & Co.

Contacts:

 

Paul Riley, PhD

Manager, Research Use Products

Diagnostica Stago, Inc.

(973) 631-1200 x4238

paul.riley@stago-us.com